Respiratory Department, Fuxing Hospital Affilicated to Capital Medical University, Beijing, China.
BMC Infect Dis. 2024 Sep 2;24(1):904. doi: 10.1186/s12879-024-09779-y.
To mitigate hospital-acquired transmission of coronavirus disease 2019 (COVID-19), various prevention and control measures have been strictly implemented in medical institutions. These stringent measures can potentially reduce the incidence of hospital-acquired respiratory infections. This study aimed to assess if there were changes in the prevalence of hospital-acquired respiratory infections during a period of national attention focused on COVID-19 prevention.
A retrospective analysis of the clinical data from adult patients with hospital-acquired respiratory infections admitted between October and December 2019 and during the same period in 2020 was performed. All patients were referred from a general hospital in Beijing China and COVID-19 patients were not treated at the hospital. Hospital-acquired respiratory infections were diagnosed based on the criteria of the Centers for Disease Control and Prevention/National Healthcare Safety Network (CDC/NHSN). A comparison of the incidence and mortality rate of hospital-acquired respiratory infections between the two selected time periods was conducted. Additionally, multivariate logistics regression analysis was used to identify mortality-associated risk factors.
This study included 2,211 patients from October to December 2019 (pre-COVID-19 pandemic) and 2,921 patients from October to December 2020 (during the COVID-19 pandemic). The incidence of hospital-acquired respiratory infections in 2019 and 2020 was 4.7% and 2.9%, respectively, with odds ratio (OR): 0.61, 95% confidence interval (CI): 0.46-0.81, and P = 0.001. In-hospital mortality of hospital-acquired respiratory infections in 2019 and 2020 was 30.5% and 38.4%, respectively, with OR: 1.42, 95%CI: 0.78-2.59, and P = 0.25. Multivariate logistics regression analysis revealed that a history of previous malignancy (OR: 2.50, 95%CI: 1.16-5.35, P = 0.02), was associated with in-hospital mortality.
The incidence of hospital-acquired respiratory infections was significantly decreased following the implementation of various prevention and control measures during the COVID-19 pandemic. A history of previous malignancy was associated with higher in-hospital mortality in older inpatients with hospital-acquired respiratory infections.
为了减轻医疗机构中 2019 年冠状病毒病(COVID-19)的医院获得性传播,已严格实施各种预防和控制措施。这些严格的措施可能会降低医院获得性呼吸道感染的发生率。本研究旨在评估在全国关注 COVID-19 预防期间,医院获得性呼吸道感染的患病率是否发生变化。
对 2019 年 10 月至 12 月和 2020 年同期因医院获得性呼吸道感染入住北京一家综合医院的成年患者的临床数据进行回顾性分析。所有患者均由中国北京的一家综合医院转诊而来,且 COVID-19 患者不在该院治疗。医院获得性呼吸道感染的诊断依据是疾病控制和预防中心/国家医疗保健安全网络(CDC/NHSN)的标准。比较了两个选定时间段内医院获得性呼吸道感染的发病率和死亡率。此外,还采用多变量逻辑回归分析确定了与死亡率相关的危险因素。
这项研究包括 2019 年 10 月至 12 月的 2211 例患者(COVID-19 大流行前)和 2020 年 10 月至 12 月的 2921 例患者。2019 年和 2020 年医院获得性呼吸道感染的发病率分别为 4.7%和 2.9%,优势比(OR):0.61,95%置信区间(CI):0.46-0.81,P=0.001。2019 年和 2020 年医院获得性呼吸道感染的院内死亡率分别为 30.5%和 38.4%,OR:1.42,95%CI:0.78-2.59,P=0.25。多变量逻辑回归分析显示,既往恶性肿瘤史(OR:2.50,95%CI:1.16-5.35,P=0.02)与院内死亡率相关。
在 COVID-19 大流行期间实施各种预防和控制措施后,医院获得性呼吸道感染的发病率显著下降。患有既往恶性肿瘤的老年住院患者发生医院获得性呼吸道感染时,院内死亡率较高。